Qiang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qiang Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Boyuan Chen
Shanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Chong Liu
Department of Neurosurgery of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Coco Chu
Institute for Immunology, Tsinghua University, Beijing, China
1 shared publication - Gregory F. Sonnenberg
Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
1 shared publication Hongzhi Liu
Shanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationHua Tang
Institute of Infection and Immunity, Medical Science and Technology Innovation Center, Shandong First Medical University, Jinan, Shandong, China
1 shared publication
Latest Publications
- 24 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6818) , 1347-1353
Fibroblasts restrain gut inflammation by IGF1-dependent regulation of innate lymphocytes
Fibroblasts exhibit phenotypic and functional heterogeneity in chronic inflammatory diseases, but how these changes impact immune outcomes remains poorly understood. We identified that a fibroblast population expressing insulin-like growth factor 1 (IGF1) was reduced in patients with inflammatory bowel disease (IBD). Using mouse models of intestinal inflammation, we found cross-talk between IGF1-expressing fibroblasts and group 3 innate lymphoid cells (ILC3s). IGF1 stimulation limited the ability of ILC3s to produce C-X-C motif chemokine ligand 10 (CXCL10) and recruit plasmacytoid dendritic cells (pDCs) to restrain gut inflammation. We propose that this regulatory pathway is conserved in human ILC3s but may become impaired in IBD. Our results define that anti-inflammatory fibroblasts safeguard the gut through regulation of an innate lymphocyte–pDC axis.
- 24 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6818) , 1347-1353
Fibroblasts restrain gut inflammation by IGF1-dependent regulation of innate lymphocytes
Fibroblasts exhibit phenotypic and functional heterogeneity in chronic inflammatory diseases, but how these changes impact immune outcomes remains poorly understood. We identified that a fibroblast population expressing insulin-like growth factor 1 (IGF1) was reduced in patients with inflammatory bowel disease (IBD). Using mouse models of intestinal inflammation, we found cross-talk between IGF1-expressing fibroblasts and group 3 innate lymphoid cells (ILC3s). IGF1 stimulation limited the ability of ILC3s to produce C-X-C motif chemokine ligand 10 (CXCL10) and recruit plasmacytoid dendritic cells (pDCs) to restrain gut inflammation. We propose that this regulatory pathway is conserved in human ILC3s but may become impaired in IBD. Our results define that anti-inflammatory fibroblasts safeguard the gut through regulation of an innate lymphocyte–pDC axis.